MX2022005406A - Forma amorfa de un receptor de componente c5a de complemento. - Google Patents

Forma amorfa de un receptor de componente c5a de complemento.

Info

Publication number
MX2022005406A
MX2022005406A MX2022005406A MX2022005406A MX2022005406A MX 2022005406 A MX2022005406 A MX 2022005406A MX 2022005406 A MX2022005406 A MX 2022005406A MX 2022005406 A MX2022005406 A MX 2022005406A MX 2022005406 A MX2022005406 A MX 2022005406A
Authority
MX
Mexico
Prior art keywords
amorphous form
receptor
complement component
compound
complement
Prior art date
Application number
MX2022005406A
Other languages
English (en)
Inventor
Yibin Zeng
Penglie Zhang
Rajinder Singh
Rebecca M Lui
Manmohan Reddy Leleti
Kwok Yau
Kenken Luong
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2022005406A publication Critical patent/MX2022005406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Secondary Cells (AREA)
  • Soft Magnetic Materials (AREA)
  • Materials For Medical Uses (AREA)

Abstract

En la presente se proporciona una forma amorfa de un receptor de componente de complemento 5a que tiene la fórmula del compuesto 1 (ver Fórmula) (compuesto 1). En la presente también se proporcionan composiciones farmacéuticas y métodos de tratamiento que utilizan la forma amorfa del compuesto 1, descrito en la presente.
MX2022005406A 2019-11-08 2020-11-06 Forma amorfa de un receptor de componente c5a de complemento. MX2022005406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932644P 2019-11-08 2019-11-08
PCT/US2020/059280 WO2021092286A1 (en) 2019-11-08 2020-11-06 Amorphous form of a complement component c5a receptor

Publications (1)

Publication Number Publication Date
MX2022005406A true MX2022005406A (es) 2022-05-24

Family

ID=75846408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005406A MX2022005406A (es) 2019-11-08 2020-11-06 Forma amorfa de un receptor de componente c5a de complemento.

Country Status (14)

Country Link
US (1) US11603356B2 (es)
EP (1) EP4054576A4 (es)
JP (1) JP2023501789A (es)
KR (1) KR20220098754A (es)
CN (1) CN114641288A (es)
AU (1) AU2020378397A1 (es)
BR (1) BR112022007489A2 (es)
CA (1) CA3155542A1 (es)
CL (1) CL2022001172A1 (es)
IL (1) IL292383A (es)
MX (1) MX2022005406A (es)
TW (1) TW202128622A (es)
WO (1) WO2021092286A1 (es)
ZA (1) ZA202305624B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220099989A (ko) 2019-11-08 2022-07-14 케모센트릭스, 인크. 보체 성분 c5a 수용체의 염 형태
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036874A1 (en) 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
MA32975B1 (fr) 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
ES2802428T3 (es) 2014-09-29 2021-01-19 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
JP2021501159A (ja) 2017-10-31 2021-01-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少
MX2020013166A (es) 2018-06-07 2021-03-29 Chemocentryx Inc Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.
CA3129019A1 (en) 2019-03-11 2020-09-17 Yong Li Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
AU2020378061A1 (en) 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
KR20220099989A (ko) 2019-11-08 2022-07-14 케모센트릭스, 인크. 보체 성분 c5a 수용체의 염 형태

Also Published As

Publication number Publication date
US11603356B2 (en) 2023-03-14
ZA202305624B (en) 2023-12-20
WO2021092286A1 (en) 2021-05-14
CA3155542A1 (en) 2021-05-14
KR20220098754A (ko) 2022-07-12
AU2020378397A1 (en) 2022-06-23
BR112022007489A2 (pt) 2022-07-12
IL292383A (en) 2022-06-01
CL2022001172A1 (es) 2023-02-17
US20210139426A1 (en) 2021-05-13
EP4054576A4 (en) 2023-12-13
TW202128622A (zh) 2021-08-01
CN114641288A (zh) 2022-06-17
EP4054576A1 (en) 2022-09-14
JP2023501789A (ja) 2023-01-19

Similar Documents

Publication Publication Date Title
ZA202305624B (en) Amorphous form of a complement component c5a receptor
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
ZA202305622B (en) Free base crystalline form of a complement component c5a receptor
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2021006695A (es) Moduladores de trex1.
WO2018153508A3 (en) INHIBITORS OF SULFOXIMINE GLYCOSIDASE
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2018039077A8 (en) Therapeutic compounds
MX2021012105A (es) Compuestos de pirrol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021007258A (es) Composiciones de esparsentan amorfas.